HC Wainwright Trims Novavax (NASDAQ:NVAX) Target Price to $19.00

Novavax (NASDAQ:NVAX – Free Report) had its price target reduced by HC Wainwright from $35.00 to $19.00 in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Novavax’s Q1 2024 earnings at ($0.85) EPS, Q3 2024 earnings […]

Leave a Reply

Your email address will not be published.

Previous post Jefferies Financial Group Reaffirms “Hold” Rating for Everi (NYSE:EVRI)
Next post International Game Technology (NYSE:IGT) Given Hold Rating at Truist Financial